三元生物(301206) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 191,894,599.16, representing a 65.03% increase compared to CNY 116,276,458.04 in the same period last year[4] - Net profit attributable to shareholders reached CNY 24,247,672.28, a significant increase of 210.54% from CNY 7,808,194.59 year-on-year[4] - Basic and diluted earnings per share both increased to CNY 0.12, marking a 200.00% rise from CNY 0.04 in the same quarter last year[4] - Operating profit reached CNY 25,374,529.81, up from CNY 12,876,263.21, reflecting a growth of 96.5% year-over-year[23] - The company's net profit attributable to shareholders increased to ¥769,310,662.69 from ¥745,062,990.41, showing a growth of about 3.2%[21] Cash Flow and Liquidity - The net cash flow from operating activities surged by 744.81% to CNY 22,158,704.92, up from CNY 2,622,930.65 in the previous year[9] - Cash flow from operating activities generated a net amount of CNY 22,158,704.92, compared to CNY 2,622,930.65 in Q1 2023, marking an increase of 743.5%[25] - Total cash and cash equivalents at the end of the period were CNY 95,348,055.91, down from CNY 142,378,891.60, a decrease of 32.9%[26] - The cash and cash equivalents decreased to ¥101,631,627.34 from ¥108,808,330.03, a decline of about 6.5%[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,882,280,669.13, reflecting a 1.49% increase from CNY 4,810,426,435.78 at the end of the previous year[4] - The total assets of the company as of the end of Q1 2024 were ¥4,882,280,669.13, compared to ¥4,810,426,435.78 at the beginning of the period, marking an increase of approximately 1.5%[21] - The company's total liabilities increased to ¥320,010,491.34 from ¥272,403,930.27, representing a growth of approximately 17.5%[21] Operating Costs and Expenses - The company reported a 44.95% increase in operating costs, attributed to higher sales volume and increased sales prices[8] - Total operating costs for Q1 2024 were ¥194,873,387.02, up from ¥135,685,668.54, indicating an increase of about 43.5%[22] - Research and development expenses rose by 34.31% compared to the previous year, indicating the company's commitment to enhancing competitiveness through increased investment in R&D[8] - Research and development expenses amounted to ¥15,833,077.03, compared to ¥11,788,523.18 in the prior period, reflecting a rise of approximately 34.3%[22] Shareholder Information - The total number of restricted shares held by major shareholders at the end of the period is 98,780,906 shares, with 127,969 shares released during the period[14] - The company reported a total of 5,110,900 shares held by Shanghai Tongyi Investment Management Co., Ltd., through various accounts[12] - The top 10 shareholders include significant holdings by Wang Shen and Wang Meihua, who are acting in concert[12] - The company has a total of 1,992,629 shares held by Beijing Yian Capital Management Co., Ltd., accounting for 0.98% of total share capital[13] - The company’s major shareholders include several private equity funds managed by Shenzhen Nanfang Xintai, with significant holdings reported[12] - The company has a total of 3,715,445 shares held by Shenzhen Nanfang Xintai Private Equity Fund, indicating strong institutional support[12] Financial Management Strategy - The company plans to use up to RMB 240 million of temporarily idle raised funds for cash management within 12 months, approved by the board and shareholders[15] - The company also intends to use up to RMB 100 million of temporarily idle self-owned funds for cash management, with a similar 12-month usage period[16] - The company’s financial management strategy includes rolling use of funds within the approved limits and timeframes[15] - The company’s management is authorized to make investment decisions within the specified limits for cash management[16] Other Financial Metrics - The weighted average return on net assets improved to 0.53%, up from 0.17% in the same period last year[4] - Other income decreased by 34.35% year-on-year, primarily due to a reduction in penalty income during the reporting period[8] - The company did not report any net profit from subsidiaries under common control during the period[24] - The report was not audited, which may affect the reliability of the financial data presented[27]